Substandard control arms question the utility of some new cancer drugs
May 02, 2019
Vinay Prasad, M.D., M.P.H., and colleagues lead an independent review of all randomized clinical trials that culminated in FDA approval of new cancer drugs between January 2013 and July 2018.